Natera Inc

NTRA

Company Profile

  • Business description

    Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

  • Contact

    13011 McCallen Pass
    Building A Suite 100
    AustinTX78753
    USA

    T: +1 650 980-9190

    E: [email protected]

    https://www.natera.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Diagnostics & Research

    Fiscal Year End

    31 December 2026

    Employees

    6,140

Stocks News & Analysis

stocks

The ASX player evolving into a defensive haven

A well-timed simplification journey as boring evolves back in vogue.
stocks

12 picks for an income portfolio - Q1 2026 update

Passive income growth continues to exceed my target.
stocks

Strong guidance from undervalued ASX share

Shares surged after the announcement of first half fiscal 2026 guidance.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,174.1012.000.13%
CAC 408,334.5890.55-1.07%
DAX 4024,381.42320.82-1.30%
Dow JONES (US)49,447.43868.711.79%
FTSE 10010,605.6961.94-0.58%
HKSE26,361.07200.740.77%
NASDAQ24,468.48365.781.52%
Nikkei 22558,824.89348.990.60%
NZX 50 Index12,915.459.780.08%
S&P 5007,126.0684.781.20%
S&P/ASX 2008,953.3013.600.15%
SSE Composite Index4,082.1330.700.76%

Market Movers